Chicago Capital’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65M | Buy |
571,825
+17,308
| +3% | +$1.97M | 1.6% | 23 |
|
|
2025
Q1 | $58.3M | Buy |
554,517
+2,929
| +0.5% | +$308K | 1.65% | 27 |
|
|
2024
Q4 | $59.1M | Buy |
551,588
+5,767
| +1% | +$618K | 1.57% | 27 |
|
|
2024
Q3 | $54.6M | Buy |
545,821
+30,875
| +6% | +$3.09M | 1.52% | 29 |
|
|
2024
Q2 | $43.4M | Buy |
514,946
+285,350
| +124% | +$24M | 1.29% | 32 |
|
|
2024
Q1 | $16.8M | Sell |
229,596
-1,915
| -0.8% | -$140K | 0.51% | 45 |
|
|
2023
Q4 | $16.5M | Sell |
231,511
-128,834
| -36% | -$9.2M | 0.6% | 41 |
|
|
2023
Q3 | $21.6M | Sell |
360,345
-63,674
| -15% | -$3.82M | 1.01% | 35 |
|
|
2023
Q2 | $30.6M | Sell |
424,019
-25,489
| -6% | -$1.84M | 1.38% | 33 |
|
|
2023
Q1 | $33.1M | Buy |
449,508
+130,454
| +41% | +$9.6M | 1.65% | 30 |
|
|
2022
Q4 | $21.3M | Sell |
319,054
-417,228
| -57% | -$27.9M | 1.18% | 32 |
|
|
2022
Q3 | $39.6M | Buy |
736,282
+17,556
| +2% | +$943K | 2.29% | 15 |
|
|
2022
Q2 | $40M | Sell |
718,726
-69,496
| -9% | -$3.87M | 2.21% | 16 |
|
|
2022
Q1 | $55.3M | Buy |
788,222
+88,583
| +13% | +$6.22M | 2.38% | 11 |
|
|
2021
Q4 | $67.4M | Sell |
699,639
-6,135
| -0.9% | -$591K | 2.51% | 14 |
|
|
2021
Q3 | $61.3M | Sell |
705,774
-29,931
| -4% | -$2.6M | 2.33% | 15 |
|
|
2021
Q2 | $60.2M | Buy |
735,705
+16,540
| +2% | +$1.35M | 2.35% | 16 |
|
|
2021
Q1 | $68.4M | Buy |
719,165
+185,600
| +35% | +$17.7M | 2.89% | 6 |
|
|
2020
Q4 | $33.1M | Sell |
533,565
-245,240
| -31% | -$15.2M | 1.48% | 30 |
|
|
2020
Q3 | $46.3M | Buy |
778,805
+347,981
| +81% | +$20.7M | 2.38% | 18 |
|
|
2020
Q2 | $30.1M | Buy |
+430,824
| New | +$30.1M | 1.74% | 25 |
|